CFP and lipoprotein glomerulopathy: These recent data have implicated properdin in the control of obesity‐related liver and kidney disease, with Cfp−/− mice showing increased body weight, decreased expression of C5a like receptor 2 (C5L2 or C5aR2), decreased insulin sensitivity, obesity‐associated glomerulopathy, and increased hepatic triglyceride.173